Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.79 HKD
Change Today -0.01 / -1.25%
Volume 350.0K
8329 On Other Exchanges
Symbol
Exchange
Hong Kong
As of 4:01 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

shenzhen neptunus interlng-h (8329) Snapshot

Open
$0.84
Previous Close
$0.80
Day High
$0.84
Day Low
$0.79
52 Week High
04/21/15 - $1.37
52 Week Low
07/8/15 - $0.60
Market Cap
1.3B
Average Volume 10 Days
878.0K
EPS TTM
$0.02
Shares Outstanding
426.0M
EX-Date
--
P/E TM
34.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for SHENZHEN NEPTUNUS INTERLNG-H (8329)

Related News

No related news articles were found.

shenzhen neptunus interlng-h (8329) Related Businessweek News

No Related Businessweek News Found

shenzhen neptunus interlng-h (8329) Details

Shenzhen Neptunus Interlong Bio-technique Company Limited researches and develops, produces, sells, and distributes gene engineering drugs and preventive biological products in the People’s Republic of China. It operates through Manufacturing and Selling of Medicines, Sales and Distribution of Medicines and Healthcare Products, and Provision of R & D Services of Modern Biological Technology segments. The company offers herbal medicine, generic, transfusion, and antitumor drugs under the Neptunus and Interlong brand names. Its primary products include recombinant human interferon a-2b for injection, recombinant human interleukin-2 for injection, and subunit influenza vaccine. The company produces chemical medicines; wholesales and retails packaging materials and pre-packaged foods; sells and distributes medicines and healthcare products; and researches and develops biological reagents and in-vitro diagnostic reagents. It sells its products in approximately 20 provinces in China; and serves approximately 500 medical organizations. The company is based in Shenzhen, the People’s Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Co., Ltd.

1,460 Employees
Last Reported Date: 03/30/15

shenzhen neptunus interlng-h (8329) Top Compensated Officers

Chief Executive Officer, General Manager and ...
Total Annual Compensation: CNY638.0K
Executive Chairman, Compliance Officer, Chair...
Total Annual Compensation: --
Executive Director
Total Annual Compensation: CNY480.0K
Compensation as of Fiscal Year 2014.

shenzhen neptunus interlng-h (8329) Key Developments

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2015

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. provided consolidated earnings guidance for the six months ended June 30, 2015. The company expects it is expected that the consolidated profit attributable to the equity holders of the Company for the six months ended June 30, 2015 may record a decrease by not more than 50% as compared with that for the corresponding period in 2014. Such decrease that may be recorded was mainly due to a decrease in revenue of the manufacturing and selling of medicines segment which resulted from a drop in the sales volume of Compound Liquorice Tablets; a slow pace in the drug tender progress for the new product namely Tegafur, Gimeracil and Oteracil Potassium Tablets; and an increase in the Group's research and development input.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported turnover of RMB 150,879,000 compared to RMB 149,067,000 a year ago. Profit from operations was RMB 21,036,000 compared to RMB 23,378,000 a year ago. Profit before taxation was RMB 18,327,000 compared to RMB 21,330,000 a year ago. Profit for the period attributable to owners of the company was RMB 10,961,000 or 0.65 cents per basic and diluted share compared to RMB 12,986,000 or 0.77 cents per basic and diluted share a year ago. During the Quarter, other revenue of the Group increased significantly as compared with the corresponding period last year, which was mainly due to the increase in interest income on bank deposits and government subsidy income.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd., Annual General Meeting, Jun 18, 2015

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd., Annual General Meeting, Jun 18, 2015., at 10:00 China Standard Time. Location: Meeting Room, 23rd Floor, Neptunus Yinhe Technology Mansion. Agenda: To consider and approve the audited consolidated financial statements of the company and its subsidiaries for the year ended 31 December 2014; to consider and approve the reports of the board of directors of the company and the auditors for the year ended 31 December 2014; to consider and approve the report of the supervisory committee of the company for the year ended 31 December 2014; to consider and approve the re-appointment of Crowe Horwath (HK) CPA Limited as the auditors of the company to hold office until the conclusion of the next annual general meeting and to authorize the Board to fix their remuneration; and to consider and approve the annual budget and final accounts of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8329:HK $0.79 HKD -0.01

8329 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8329.
View Industry Companies
 

Industry Analysis

8329

Industry Average

Valuation 8329 Industry Range
Price/Earnings 34.5x
Price/Sales 1.7x
Price/Book 2.1x
Price/Cash Flow 34.5x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHENZHEN NEPTUNUS INTERLNG-H, please visit www.interlong.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.